Stockscreener 앱 받기
37.72
0.88%
0.33
시간 외 거래:
37.71
-0.010
-0.03%
전일 마감가:
$37.39
열려 있는:
$37.14
하루 거래량:
1.90M
Relative Volume:
0.52
시가총액:
$10.15B
수익:
$2.17B
순이익/손실:
$521.27M
주가수익비율:
21.31
EPS:
1.77
순현금흐름:
$633.79M
1주 성능:
+1.23%
1개월 성능:
-13.31%
6개월 성능:
+12.66%
1년 성능:
+38.83%
1일 변동 폭
$37.10
$37.91
1주일 범위
$36.37
$37.91
52주 변동 폭
$25.12
$49.62
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
EXEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
37.72 | 10.15B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2024-09-19 | 개시 | UBS | Neutral |
| 2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 개시 | BTIG Research | Buy |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-09-26 | 개시 | H.C. Wainwright | Buy |
| 2023-08-22 | 재확인 | Oppenheimer | Outperform |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 재개 | Piper Sandler | Overweight |
| 2023-03-09 | 개시 | Wells Fargo | Overweight |
| 2023-01-26 | 개시 | Credit Suisse | Outperform |
| 2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-03 | 재개 | Jefferies | Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-15 | 개시 | H.C. Wainwright | Buy |
| 2021-05-18 | 재개 | Goldman | Sell |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 개시 | Goldman | Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Underweight |
| 2018-05-11 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-16 | 재확인 | SunTrust | Buy |
| 2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-12 | 재확인 | Needham | Buy |
| 2017-07-14 | 개시 | SunTrust | Buy |
| 2017-03-31 | 개시 | Needham | Buy |
| 2017-03-16 | 개시 | Oppenheimer | Perform |
| 2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
ATTENTION EXEL Shareholders: Lost Money on Exelixis, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Ongoing Securities Investigation into Exelixis, Inc. (EXEL)Contact Levi & Korsinsky - ACCESS Newswire
Exelixis’ CABOMETYX Receives EU Approval for Neuroendocrine Tumor Treatment - Insider Monkey
Exelixis reports Q2 net product revenues 2% below consensus estimate. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - FinancialContent
Identifying reversal signals in Exelixis Inc.Trend Confirmation Scanner with Entry Focus - Newser
Relative strength of Exelixis Inc. in sector analysisProfit Target Planning with Exit Confidence - Newser
Can Exelixis Inc. be recession proofTriple Digit Stock Opportunities - sisaissue.com
Live market analysis of Exelixis Inc.Free Daily Growth Stock Pick Reports - Newser
Lost Money on Exelixis, Inc. (EXEL)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Levi & Korsinsky Investigates Exelixis, Inc. (EXEL) Over Possible Securities Fraud - ACCESS Newswire
Exelixis, Inc. (NASDAQ:EXEL) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - 富途牛牛
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Mutual of America Capital Management LLC - Defense World
What Fibonacci levels say about Exelixis Inc. reboundTechnical Long-Term Outlook and Recap Guide - Newser
Momentum Screeners Rank Exelixis Inc. in Top 5 TodaySafe Entry Stock Watch Suggestions for Cautious Traders - beatles.ru
Will Exelixis Inc. continue its uptrendDaily Technical Forecast for Quick Gains - Newser
Is it too late to sell Exelixis Inc.Strategy Builder for Growth Focused Traders - Newser
How to use a screener to detect Exelixis Inc. breakoutsRisk Shielded Trade Watch with Analysis - Newser
Investors in Exelixis, Inc. (EXEL) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Exelixis, Inc. (EXEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Signal strength of Exelixis Inc. stock in tech scannersRSI Divergence and Support Breakout Analysis - Newser
Levi & Korsinsky Investigates Possible Securities Fraud by Exelixis, Inc. (EXEL) - ACCESS Newswire
Is Exelixis Inc. stock bottoming outHistorical Market Behavior and Trend Summary - Newser
Potential Securities Fraud: Levi & Korsinsky Investigates Exelixis, Inc. (EXEL) - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc.EXEL - PR Newswire
Exelixis, Inc. (EXEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Can Exelixis Inc. recover in the next quarterBuy and Hold Strategy for Capital Safety - Newser
Why Exelixis Inc. stock attracts strong analyst attentionFree Optimized Watchlist With Daily Adjustments - Newser
Avantax Advisory Services Inc. Makes New $551,000 Investment in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Will Exelixis Inc. see short term momentumFundamental Forecast for Undervalued Stocks - Newser
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Exelixis, Inc. (EXEL) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Securities Investigation: Levi & Korsinsky Investigates Exelixis, Inc. (EXEL) on Behalf of Investors - ACCESS Newswire
Exelixis, Inc. : The cure to cancer? - MarketScreener
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock? - TradingView
Exelixis (NASDAQ:EXEL) Cut to “Buy” at Wall Street Zen - Defense World
Exelixis EXEL Q2 2025 Earnings Call Transcript - AOL.com
Bronstein, Gewirtz & Grossman, LLC Encourages Exelixis, Inc. (EXEL) Investors to Inquire about Securities Investigation - ACCESS Newswire
Live market analysis of Exelixis IncReal Time Growth Signal with Smart Setup - Newser
Don't Overlook Exelixis (EXEL) International Revenue Trends While Assessing the Stock - Yahoo Finance
Exelixis Inc. Chart Enters High Volatility ZoneTriple Digit Return Stock Predictions Released - beatles.ru
Exelixis (EXEL) Tumbles 16.8% as Q2 Earnings Disappoint - MSN
How strong is Exelixis Inc. company’s balance sheetBoost your returns with professional guidance - Jammu Links News
What makes Exelixis Inc. stock price move sharplyMassive wealth growth - Jammu Links News
What are analysts’ price targets for Exelixis Inc. in the next 12 monthsSky-high return potential - Jammu Links News
Is Exelixis Inc. a good long term investmentOutstanding trading profits - Jammu Links News
EXEL ALERT: Levi & Korsinsky Investigates Exelixis, Inc. for Possible Securities Fraud Violations - ACCESS Newswire
How does Exelixis Inc. compare to its industry peersBreakthrough capital growth - Jammu Links News
How many analysts rate Exelixis Inc. as a “Buy”Capitalize on market momentum for maximum profit - Jammu Links News
Did You Suffer Losses in Exelixis, Inc. (EXEL)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Why is Exelixis Inc. stock attracting strong analyst attentionBreakthrough profit margins - Jammu Links News
What analysts say about Exelixis Inc. stockSuperior investment outcomes - Jammu Links News
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):